Angiotensin II - La Jolla Pharmaceutical Company
Alternative Names: ANGII; Angiotensin-II - LJPC; Angiotensin-II acetate; Giapreza; LJPC-501Latest Information Update: 08 Mar 2024
At a glance
- Originator La Jolla Pharmaceutical Company
- Developer La Jolla Pharmaceutical Company; PAION
- Class Angiotensins; Anti-infectives; Anti-inflammatories; Antihypotensives; Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
- Mechanism of Action Angiotensin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypotension
- Clinical Phase Unknown SARS-CoV-2 sepsis
- Discontinued Hepatorenal syndrome
Most Recent Events
- 15 Feb 2023 La Jolla Pharmaceutical Company has licensed patent protection for angiotensin II in USA and other countries
- 15 Feb 2023 La Jolla Pharmaceutical Company has licensed patents pending for angiotensin II in USA and other countries
- 15 Feb 2023 La Jolla Pharmaceutical Company has patent protection for angiotensin II in USA and other countries